Amgen Inc. (AMGN) 10-Year Financial Performance & Capital Metrics

AMGN • • Industrial / General

HealthcareLarge PharmaSpecialty BiopharmaceuticalsOncology-Focused Innovators

AboutAmgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.Show more

Revenue $33.42B +18.6%
EBITDA $12.85B +7.4%
Net Income $4.09B -39.1%
EPS (Diluted) 7.56 -39.5%
Gross Margin 61.53% -12.3%
EBITDA Margin 38.45% -9.4%
Operating Margin 21.71% -22.5%
Net Margin 12.24% -48.6%
ROE 67.55% -50.3%
ROIC 9.56% -23.4%
Debt/Equity 10.23 -1.4%
Interest Coverage 2.30 -16.2%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Excellent 3Y average ROE of 109.9%
✓FCF machine: 31.1% free cash flow margin
✓14 consecutive years of dividend growth
✓High quality earnings: Operating CF exceeds net income
✓Healthy dividend yield of 2.7%
✓Healthy 5Y average net margin of 22.4%

✗Weaknesses

✗High debt to equity ratio of 10.2x
✗Profits declining 12.2% over 5 years
✗Dividend payout exceeds 100% of earnings
✗Expensive at 30.4x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y5.24%

5Y7.43%

3Y8.76%

TTM10.53%

Profit (Net Income) CAGR

10Y-2.29%

5Y-12.21%

3Y-11.46%

TTM65.6%

EPS CAGR

10Y1.21%

5Y-10.11%

3Y-9.74%

TTM65.69%

ROCE

10Y Avg15.46%

5Y Avg15.09%

3Y Avg13.87%

Latest9.84%

Peer Comparison

Oncology-Focused Innovators

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
GILDGilead Sciences, Inc.	150.44B	121.26	319.11	6.04%	27.88%	37.8%	6.85%	1.39
AMGNAmgen Inc.	177.71B	330.03	43.65	18.57%	19.48%	72.82%	5.85%	10.23
CELG-RIBristol-Myers Squibb Company Ce		0.16	-0.04	7.32%	12.57%	32.47%		3.12
BMYBristol-Myers Squibb Company	115.26B	56.62	-12.84	7.32%	12.57%	32.47%	12.1%	3.12

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	21.66B	22.99B	22.85B	23.75B	23.36B	25.42B	25.98B	26.32B	28.19B	33.42B
Revenue Growth %	0.08%	0.06%	-0.01%	0.04%	-0.02%	0.09%	0.02%	0.01%	0.07%	0.19%
Cost of Goods Sold+	4.23B	4.16B	4.07B	4.1B	4.36B	6.16B	6.45B	6.41B	8.41B	12.86B
COGS % of Revenue	0.2%	0.18%	0.18%	0.17%	0.19%	0.24%	0.25%	0.24%	0.3%	0.38%
Gross Profit+	17.43B	18.83B	18.78B	19.65B	19.01B	19.27B	19.52B	19.92B	19.77B	20.57B
Gross Margin %	0.8%	0.82%	0.82%	0.83%	0.81%	0.76%	0.75%	0.76%	0.7%	0.62%
Gross Profit Growth %	0.11%	0.08%	-0%	0.05%	-0.03%	0.01%	0.01%	0.02%	-0.01%	0.04%
Operating Expenses+	8.96B	9.04B	8.81B	9.38B	9.33B	10.13B	11.89B	10.35B	11.84B	13.31B
OpEx % of Revenue	0.41%	0.39%	0.39%	0.4%	0.4%	0.4%	0.46%	0.39%	0.42%	0.4%
Selling, General & Admin	4.85B	5.06B	4.87B	5.33B	5.15B	5.73B	5.37B	5.41B	6.18B	7.1B
SG&A % of Revenue	0.22%	0.22%	0.21%	0.22%	0.22%	0.23%	0.21%	0.21%	0.22%	0.21%
Research & Development	4.07B	3.84B	3.56B	3.74B	4.12B	4.21B	6.32B	4.43B	4.78B	5.96B
R&D % of Revenue	0.19%	0.17%	0.16%	0.16%	0.18%	0.17%	0.24%	0.17%	0.17%	0.18%
Other Operating Expenses	49M	133M	375M	314M	66M	189M	194M	503M	879M	248M
Operating Income+	8.47B	9.79B	9.97B	10.26B	9.67B	9.14B	7.64B	9.57B	7.9B	7.26B
Operating Margin %	0.39%	0.43%	0.44%	0.43%	0.41%	0.36%	0.29%	0.36%	0.28%	0.22%
Operating Income Growth %	0.37%	0.16%	0.02%	0.03%	-0.06%	-0.06%	-0.16%	0.25%	-0.17%	-0.08%
EBITDA+	10.58B	11.9B	11.93B	12.21B	11.88B	12.74B	11.04B	12.98B	11.97B	12.85B
EBITDA Margin %	0.49%	0.52%	0.52%	0.51%	0.51%	0.5%	0.42%	0.49%	0.42%	0.38%
EBITDA Growth %	0.28%	0.12%	0%	0.02%	-0.03%	0.07%	-0.13%	0.18%	-0.08%	0.07%
D&A (Non-Cash Add-back)	2.11B	2.1B	1.96B	1.95B	2.21B	3.6B	3.4B	3.42B	4.07B	5.59B
EBIT	9.07B	10.42B	10.9B	10.94B	10.43B	9.39B	7.9B	8.75B	10.73B	7.76B
Net Interest Income+	-492M	-631M	-376M	-718M	-702M	-1.26B	-1.2B	-1.41B	-2.88B	-3.15B
Interest Income	603M	629M	928M	674M	587M	0	0	0	0	0
Interest Expense	1.09B	1.26B	1.3B	1.39B	1.29B	1.26B	1.2B	1.41B	2.88B	3.15B
Other Income/Expense	-492M	-631M	-376M	-718M	-536M	-1.01B	-938M	-2.22B	-42M	-2.65B
Pretax Income+	7.98B	9.16B	9.6B	9.54B	9.14B	8.13B	6.7B	7.35B	7.86B	4.61B
Pretax Margin %	0.37%	0.4%	0.42%	0.4%	0.39%	0.32%	0.26%	0.28%	0.28%	0.14%
Income Tax+	1.04B	1.44B	7.62B	1.15B	1.3B	869M	808M	794M	1.14B	519M
Effective Tax Rate %	0.87%	0.84%	0.21%	0.88%	0.86%	0.89%	0.88%	0.89%	0.86%	0.89%
Net Income+	6.94B	7.72B	1.98B	8.39B	7.84B	7.26B	5.89B	6.55B	6.72B	4.09B
Net Margin %	0.32%	0.34%	0.09%	0.35%	0.34%	0.29%	0.23%	0.25%	0.24%	0.12%
Net Income Growth %	0.35%	0.11%	-0.74%	3.24%	-0.07%	-0.07%	-0.19%	0.11%	0.03%	-0.39%
Net Income (Continuing)	6.94B	7.72B	1.98B	8.39B	7.84B	7.26B	5.89B	6.55B	6.72B	4.09B
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	9.06	10.24	2.69	12.62	12.88	12.31	10.28	12.11	12.49	7.56
EPS Growth %	0.35%	0.13%	-0.74%	3.69%	0.02%	-0.04%	-0.16%	0.18%	0.03%	-0.39%
EPS (Basic)	9.15	10.32	2.71	12.70	12.96	12.40	10.34	12.18	12.56	7.62
Diluted Shares Outstanding	766M	754M	735M	665M	609M	590M	573M	541M	538M	541M
Basic Shares Outstanding	758M	748M	731M	661M	605M	586M	570M	538M	535M	541M
Dividend Payout Ratio	0.35%	0.39%	1.7%	0.42%	0.45%	0.52%	0.68%	0.64%	0.68%	1.18%

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	38.52B	46.01B	49.48B	37.62B	18.44B	21.14B	19.39B	22.19B	30.33B	29.03B
Cash & Short-Term Investments	31.38B	38.09B	41.68B	29.3B	8.91B	10.65B	8.04B	9.3B	10.94B	11.97B
Cash Only	4.14B	3.24B	3.8B	6.95B	6.04B	6.27B	7.99B	7.63B	10.94B	11.97B
Short-Term Investments	27.24B	34.84B	37.88B	22.36B	2.87B	4.38B	48M	1.68B	0	0
Accounts Receivable	3B	3.17B	3.24B	3.58B	4.06B	4.53B	5.84B	6.39B	7.94B	7.5B
Days Sales Outstanding	50.47	50.25	51.71	55.03	63.39	64.96	82.04	88.63	102.83	81.91
Inventory	2.44B	2.75B	2.83B	2.94B	3.58B	3.89B	4.09B	4.93B	9.52B	7B
Days Inventory Outstanding	210.26	240.73	254.22	261.67	300.31	230.71	231.08	280.9	412.84	198.65
Other Current Assets	1.7B	2.02B	1.73B	1.79B	1.89B	2.08B	200M	355M	281M	419M
Total Non-Current Assets+	32.93B	31.62B	30.48B	28.8B	41.27B	41.8B	41.78B	42.94B	66.82B	62.81B
Property, Plant & Equipment	4.91B	4.96B	4.99B	4.96B	4.93B	4.89B	5.18B	5.43B	5.94B	6.54B
Fixed Asset Turnover	4.41x	4.63x	4.58x	4.79x	4.74x	5.20x	5.01x	4.85x	4.74x	5.11x
Goodwill	14.79B	14.75B	14.76B	14.7B	14.7B	14.69B	14.89B	15.53B	18.63B	18.64B
Intangible Assets	11.64B	10.28B	8.61B	7.44B	19.41B	16.59B	15.18B	16.08B	32.64B	27.7B
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	1.6B	1.63B	2.12B	1.7B	2.22B	5.64B	6.52B	5.9B	9.61B	9.93B
Total Assets+	71.58B	77.63B	79.95B	66.42B	59.71B	62.95B	61.16B	65.12B	97.15B	91.84B
Asset Turnover	0.30x	0.30x	0.29x	0.36x	0.39x	0.40x	0.42x	0.40x	0.29x	0.36x
Asset Growth %	0.04%	0.08%	0.03%	-0.17%	-0.1%	0.05%	-0.03%	0.06%	0.49%	-0.05%
Total Current Liabilities+	8.66B	11.2B	9.02B	13.49B	12.84B	11.65B	12.18B	15.69B	18.39B	23.1B
Accounts Payable	965M	917M	1.35B	1.21B	1.37B	1.42B	1.37B	1.57B	1.59B	1.91B
Days Payables Outstanding	83.33	80.42	121.28	107.43	114.88	84.21	77.25	89.57	68.97	54.16
Short-Term Debt	2.25B	4.4B	1.15B	4.42B	2.95B	91M	87M	1.59B	1.44B	3.55B
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	1.31B	1.36B	1.27B	1.54B	1.54B	1.57B	1.62B	1.1B	1.38B	1.33B
Current Ratio	4.45x	4.11x	5.49x	2.79x	1.44x	1.81x	1.59x	1.41x	1.65x	1.26x
Quick Ratio	4.16x	3.86x	5.17x	2.57x	1.16x	1.48x	1.26x	1.10x	1.13x	0.95x
Cash Conversion Cycle	177.4	210.56	184.65	209.27	248.82	211.46	235.86	279.96	446.71	226.4
Total Non-Current Liabilities+	34.7B	36.55B	45.69B	40.43B	37.2B	41.89B	42.28B	45.77B	72.53B	62.86B
Long-Term Debt	29.18B	30.19B	34.19B	29.51B	26.95B	32.9B	33.22B	37.35B	63.17B	56.55B
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	2.24B	2.44B	1.17B	864M	606M	0	0	11M	2.35B	1.62B
Other Non-Current Liabilities	3.28B	3.92B	10.34B	10.05B	9.64B	8.99B	9.06B	8.41B	7.01B	4.7B
Total Liabilities	43.37B	47.75B	54.71B	53.92B	50.03B	53.54B	54.47B	61.46B	90.92B	85.96B
Total Debt+	31.43B	34.6B	35.34B	33.93B	29.9B	32.99B	33.31B	38.95B	64.61B	60.1B
Net Debt	27.29B	31.36B	31.54B	26.98B	23.87B	26.72B	25.32B	31.32B	53.67B	48.13B
Debt / Equity	1.12x	1.16x	1.40x	2.71x	3.09x	3.51x	4.97x	10.64x	10.37x	10.23x
Debt / EBITDA	2.97x	2.91x	2.96x	2.78x	2.52x	2.59x	3.02x	3.00x	5.40x	4.68x
Net Debt / EBITDA	2.58x	2.64x	2.64x	2.21x	2.01x	2.10x	2.29x	2.41x	4.48x	3.75x
Interest Coverage	7.74x	7.77x	7.65x	7.37x	7.51x	7.24x	6.38x	6.80x	2.75x	2.30x
Total Equity+	28.08B	29.88B	25.24B	12.5B	9.67B	9.41B	6.7B	3.66B	6.23B	5.88B
Equity Growth %	0.09%	0.06%	-0.16%	-0.5%	-0.23%	-0.03%	-0.29%	-0.45%	0.7%	-0.06%
Book Value per Share	36.66	39.62	34.34	18.80	15.88	15.95	11.69	6.77	11.58	10.86
Total Shareholders' Equity	28.08B	29.88B	25.24B	12.5B	9.67B	9.41B	6.7B	3.66B	6.23B	5.88B
Common Stock	30.65B	30.78B	30.99B	31.25B	31.53B	31.8B	32.1B	32.51B	33.07B	33.53B
Retained Earnings	-2.09B	-438M	-5.07B	-17.98B	-21.33B	-21.41B	-24.6B	-28.62B	-26.55B	-27.59B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-480M	-471M	-679M	-769M	-528M	-985M	-796M	-231M	-289M	-66M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	9.08B	10.35B	11.18B	11.3B	9.15B	10.5B	9.26B	9.72B	8.47B	11.49B
Operating CF Margin %	0.42%	0.45%	0.49%	0.48%	0.39%	0.41%	0.36%	0.37%	0.3%	0.34%
Operating CF Growth %	0.06%	0.14%	0.08%	0.01%	-0.19%	0.15%	-0.12%	0.05%	-0.13%	0.36%
Net Income	6.94B	7.72B	1.98B	8.39B	7.84B	7.26B	5.89B	6.55B	6.72B	4.09B
Depreciation & Amortization	2.11B	2.1B	1.96B	1.95B	2.21B	3.6B	3.4B	3.42B	4.07B	5.59B
Stock-Based Compensation	322M	311M	329M	311M	308M	330M	341M	401M	431M	530M
Deferred Taxes	-607M	183M	-1.33B	-363M	-289M	-287M	-453M	-1.2B	-1.27B	-1.23B
Other Non-Cash Items	-399M	32M	334M	386M	-186M	-195M	1.28B	1.28B	-991M	141M
Working Capital Changes	714M	1M	7.91B	622M	-731M	-216M	-1.19B	-733M	-484M	2.37B
Change in Receivables	-420M	-214M	-58M	-378M	-504M	-427M	-429M	-746M	-1.01B	441M
Change in Inventory	481M	-80M	133M	-3M	-66M	-215M	-165M	-742M	491M	2.53B
Change in Payables	-12M	-44M	424M	-143M	164M	45M	-69M	154M	-402M	312M
Cash from Investing+	-5.55B	-8.66B	-4.02B	14.34B	5.71B	-5.4B	733M	-6.04B	-26.2B	-1.05B
Capital Expenditures	-649M	-837M	-664M	-738M	-618M	-608M	-880M	-936M	-1.11B	-1.1B
CapEx % of Revenue	0.03%	0.04%	0.03%	0.03%	0.03%	0.02%	0.03%	0.04%	0.04%	0.03%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-118M	-123M	-148M	-145M	-52M	-75M	-35M	-12M	225M	50M
Cash from Financing+	-3.12B	-2.6B	-6.59B	-22.49B	-15.77B	-4.87B	-8.27B	-4.04B	21.05B	-9.41B
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-2.4B	-3B	-3.37B	-3.51B	-3.51B	-3.75B	-4.01B	-4.2B	-4.56B	-4.83B
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-172M	-229M	-140M	-68M	-42M	-90M	-78M	-103M	-72M	-124M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	8.43B	9.52B	10.51B	10.56B	8.53B	9.89B	8.38B	8.79B	7.36B	10.39B
FCF Margin %	0.39%	0.41%	0.46%	0.44%	0.37%	0.39%	0.32%	0.33%	0.26%	0.31%
FCF Growth %	0.12%	0.13%	0.1%	0%	-0.19%	0.16%	-0.15%	0.05%	-0.16%	0.41%
FCF per Share	11.00	12.62	14.30	15.88	14.01	16.76	14.63	16.24	13.68	19.21
FCF Conversion (FCF/Net Income)	1.31x	1.34x	5.65x	1.35x	1.17x	1.45x	1.57x	1.48x	1.26x	2.81x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	25.77%	26.65%	7.18%	44.48%	70.73%	76.13%	73.16%	126.47%	135.79%	67.55%
Return on Invested Capital (ROIC)	11.75%	12.6%	12.68%	15.99%	19.87%	19.68%	16.81%	21.42%	12.48%	9.56%
Gross Margin	80.49%	81.9%	82.19%	82.73%	81.35%	75.77%	75.16%	75.66%	70.15%	61.53%
Net Margin	32.03%	33.59%	8.66%	35.35%	33.57%	28.57%	22.68%	24.89%	23.83%	12.24%
Debt / Equity	1.12x	1.16x	1.40x	2.71x	3.09x	3.51x	4.97x	10.64x	10.37x	10.23x
Interest Coverage	7.74x	7.77x	7.65x	7.37x	7.51x	7.24x	6.38x	6.80x	2.75x	2.30x
FCF Conversion	1.31x	1.34x	5.65x	1.35x	1.17x	1.45x	1.57x	1.48x	1.26x	2.81x
Revenue Growth	7.97%	6.14%	-0.62%	3.93%	-1.62%	8.83%	2.18%	1.32%	7.09%	18.57%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Other Products	-	-	-	4.31B	4.96B	6.57B	5.85B	5.57B	5.26B	5.63B
Other Products Growth	-	-	-	-	15.16%	32.57%	-11.00%	-4.80%	-5.51%	6.97%
Prolia	1.31B	1.64B	1.97B	2.29B	2.67B	2.76B	3.25B	3.63B	4.05B	4.37B
Prolia Growth	-	24.62%	20.37%	16.41%	16.63%	3.41%	17.55%	11.70%	11.58%	8.05%
ENBREL	5.36B	5.96B	5.43B	5.01B	5.23B	5B	4.46B	4.12B	3.7B	3.32B
ENBREL Growth	-	11.20%	-8.92%	-7.71%	4.23%	-4.40%	-10.63%	-7.79%	-10.20%	-10.31%
XGEVA	1.41B	1.53B	1.57B	1.79B	1.94B	1.9B	2.02B	2.01B	2.11B	2.23B
XGEVA Growth	-	8.83%	3.01%	13.40%	8.34%	-1.86%	6.27%	-0.20%	4.87%	5.35%
Repatha (evolocumab)	-	-	-	-	-	887M	1.12B	1.3B	1.64B	2.22B
Repatha (evolocumab) Growth	-	-	-	-	-	-	25.93%	16.03%	26.16%	35.90%
Otezla	-	-	-	-	-	2.19B	2.25B	2.29B	2.19B	2.13B
Otezla Growth	-	-	-	-	-	-	2.46%	1.73%	-4.37%	-2.83%
TEPEZZA	-	-	-	-	-	-	-	-	448M	1.85B
TEPEZZA Growth	-	-	-	-	-	-	-	-	-	313.17%
EVENITY	-	-	-	-	-	-	-	-	-	1.56B
EVENITY Growth	-	-	-	-	-	-	-	-	-	-
Kyprolis	512M	692M	835M	-	1.04B	1.06B	1.11B	1.25B	1.4B	1.5B
Kyprolis Growth	-	35.16%	20.66%	-	-	2.01%	4.04%	12.55%	12.51%	7.13%
Nplate	525M	584M	642M	-	-	-	1.03B	1.31B	1.48B	1.46B
Nplate Growth	-	11.24%	9.93%	-	-	-	-	27.26%	13.01%	-1.42%
Product and Service, Other	-	-	-	1.21B	1.16B	1.18B	1.68B	1.52B	1.28B	1.4B
Product and Service, Other Growth	-	-	-	-	-4.61%	2.25%	42.06%	-9.51%	-15.90%	9.22%
Aranesp	1.95B	2.09B	2.05B	1.88B	1.73B	1.57B	1.48B	1.42B	1.36B	1.34B
Aranesp Growth	-	7.28%	-1.91%	-8.57%	-7.88%	-9.31%	-5.61%	-3.99%	-4.15%	-1.47%
BLINCYTO	-	115M	175M	-	-	-	-	-	861M	1.22B
BLINCYTO Growth	-	-	52.17%	-	-	-	-	-	-	41.23%
KRYSTEXXA	-	-	-	-	-	-	-	-	272M	1.19B
KRYSTEXXA Growth	-	-	-	-	-	-	-	-	-	335.66%
Vectibix	549M	611M	642M	-	-	-	-	-	984M	1.04B
Vectibix Growth	-	11.29%	5.07%	-	-	-	-	-	-	6.20%
TEZSPIRE	-	-	-	-	-	-	-	-	-	972M
TEZSPIRE Growth	-	-	-	-	-	-	-	-	-	-
Evenity	-	-	-	-	-	-	-	787M	1.16B	-
Evenity Growth	-	-	-	-	-	-	-	-	47.40%	-
Neulasta	4.71B	4.65B	4.53B	4.47B	3.22B	2.29B	1.73B	1.13B	-	-
Neulasta Growth	-	-1.42%	-2.45%	-1.30%	-28.02%	-28.81%	-24.38%	-35.06%	-	-
EPOGEN	1.86B	1.28B	1.1B	1.01B	867M	-	-	-	-	-
EPOGEN Growth	-	-30.93%	-14.51%	-7.85%	-14.16%	-	-	-	-	-
Sensipar Mimpara	1.42B	1.58B	1.72B	1.77B	551M	-	-	-	-	-
Sensipar Mimpara Growth	-	11.80%	8.60%	3.26%	-68.94%	-	-	-	-	-
NEUPOGEN	1.05B	765M	549M	-	-	-	-	-	-	-
NEUPOGEN Growth	-	-27.07%	-28.24%	-	-	-	-	-	-	-
Repatha	-	141M	319M	-	-	-	-	-	-	-
Repatha Growth	-	-	126.24%	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	17.17B	18.33B	18.03B	18.36B	17.22B	18.5B	18.19B	18.59B	19.81B	23.86B
UNITED STATES Growth	-	6.75%	-1.62%	1.82%	-6.18%	7.39%	-1.63%	2.20%	6.51%	20.48%
Non-US	4.5B	4.67B	4.82B	5.39B	6.14B	6.93B	7.79B	7.73B	8.38B	9.56B
Non-US Growth	-	3.78%	3.32%	11.80%	13.90%	12.87%	12.37%	-0.73%	8.49%	14.04%

Frequently Asked Questions

Valuation & Price

Amgen Inc. (AMGN) has a price-to-earnings (P/E) ratio of 43.7x. This suggests investors expect higher future growth.

Growth & Financials

Amgen Inc. (AMGN) reported $35.96B in revenue for fiscal year 2024. This represents a 131% increase from $15.58B in 2011.

Amgen Inc. (AMGN) grew revenue by 18.6% over the past year. This is strong growth.

Yes, Amgen Inc. (AMGN) is profitable, generating $7.00B in net income for fiscal year 2024 (12.2% net margin).

Dividend & Returns

Yes, Amgen Inc. (AMGN) pays a dividend with a yield of 2.71%. This makes it attractive for income-focused investors.

Amgen Inc. (AMGN) has a return on equity (ROE) of 67.6%. This is excellent, indicating efficient use of shareholder capital.

Amgen Inc. (AMGN) generated $11.54B in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...